A new pill for postpartum depression?

A pill to treat postpartum depression? It’s here.

5:00 AM

View  Transcript

The fast-acting pill, paired with psychosocial treatment, offers a comprehensive treatment plan, but price concerns remain. Visit Health Lab to read the full story.



Welcome to Health Lab, your destination for news and stories about the future of healthcare. Today: A pill to treat postpartum depression? It’s here. The fast-acting pill, paired with psychosocial treatment, offers a comprehensive treatment plan, but price concerns remain.

The first oral medication to treat postpartum depression, zuranolone (branded Zurzuvae), received approval from the FDA in August 2023.

Taken orally once a day for 14 days, the pill starts relieving depressive symptoms after about three days and the effects last up to 45 days.

Zuranolone supplies a mimic of allopregnanolone – a neurohormone that decreases rapidly after pregnancy – that acts on receptors to reverse the withdrawal effects that impact mood.

This mechanism differs from most anti-depressants, which target neurotransmitters and take up to six to eight weeks to take effect.

The fast-acting pill offers more convenience than the postpartum depression infusion treatment, brexanolone (branded Zulresso), which has been available since 2019, but cost concerns remain.

As with all mental health medications, zuranolone should be paired with psychosocial treatment to treat all factors contributing to the disease.

“We get excited about new medicines – which are wonderful – but we put a lot of resources towards developing medicines when known psychosocial risks need our attention as well. These risks often get forgotten and stay unaddressed,” said Maria Muzik, M.D., M.Sc., a professor in the Michigan Medicine departments of psychiatry and obstetrics and gynecology.

Like during depressive periods at any other time in life, postpartum depression is characterized by symptoms such as low energy, sad or irritable mood, sleeping/eating too much or too little, or not feeling joy in expected activities, including caring for the baby. In severe cases, postpartum depression can be life-threatening as mothers may experience thoughts of harming themselves or their child.

Both biological factors, like the shift in the hormonal landscape after birth, and psychosocial factors contribute to the development of postpartum depression, says Muzik.

“Because postpartum depression has a multifactorial origin, we also need multilevel treatments. In clinical practice, we first address psychosocial factors with a wide range of evidence-based psychotherapies and support and then address biological factors with medications,” said Muzik.

Psychoeducation should come first, says Muzik. Women often don’t realize they are depressed or downplay their symptoms.

“Many women feel guilty for their depressive symptoms, and we must educate them that their symptoms are part of a treatable illness. They are not weak.”

Peer-to-peer support groups, where moms support other moms, are enormously helpful. Psychotherapy, like cognitive behavioral therapy, interpersonal therapy, or parent-infant psychotherapy can help parents work through their anxious or depressive feelings and support their parenting confidence while also developing strategies to avert future flare ups.

Until now, the mainstay of biological treatment for postpartum depression were anti-depressants or anti-anxiety medications that increased serotonin levels in the brain called selective serotonin reuptake inhibitors or SSRIs.

The newly approved zuranalone will offer another, mechanistically totally different, option for treating the biological underpinnings of postpartum depression.

“Postpartum depression co-occurs with anxiety even more so than major depressive disorder,” said Muzik.

“Zuranolone works on allopregnanolone receptors to decrease anxiety, insomnia, and depression associated with postpartum depression.”

Side effects of the medication include dizziness and sedation which prohibits patients from driving or operating machinery while taking the medication.

Patients cannot take the medication while pregnant and cannot breastfeed while taking the medication and for a week afterwards.

Importantly, zuranolone has an addictive potential and should be avoided in individuals with a history of addiction.

It is not yet clear whether zuranolone will remain as costly as its intravenous predecessor, brexanalone.

Currently, zuranolone is FDA approved only for the treatment of postpartum depression and not for major depressive disorder.

Sage Therapeutics, the drug manufacturer, originally projected the price for zuranolone to stay under $10,000 if it was also approved for major depressive disorder. Now that the market is smaller, the price will likely increase.

If it’s not fully subsidized by Medicare or insurance companies, this medication will heighten health care inequities, says Muzik.

Those who can afford the medication or have insurance that covers it will have access and those who do not will not have access.

“I am very excited, but I also wonder what the ramifications are,” continued Muzik.

“My biggest concern is how will those who have the greatest risk and need get access to the medication?"

For more on this story and others like it, visit michiganmedicine.org/health-lab. Health Lab is a part of the Michigan Medicine Podcast Network and is produced by the Michigan Medicine Department of Communication. You can subscribe to Health Lab wherever you listen to podcasts.

More Articles About: Depression Postpartum Depression Psychiatry obstetrics and gynecology drugs podcast Michigan Medicine
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast

Listen to more Health Lab podcasts - a part of the Michigan Medicine Podcast Network.

Featured News & Stories Health Lab Podcast
Health Lab Podcast
Worry and anxiety is impacting falling asleep for kids
Certain nighttime habits can either help or hurt sleep issues in young children.
Firearms and mental health
Health Lab
Firearms and mental health: 8 top facts to know
For people with mental health conditions, whether diagnosed or not, easy firearm access during a crisis can be dangerous. There experts offer tips for how to reduce the risk.
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
New research launched to address health disparities in abnormal menstrual bleeding and anemia
A $5.6 million grant helps launch research to improve screening and treatment for a gynecologic disorder disproportionately impacting Black and Hispanic populations.
vines all over growing out of purple woman drawing pink background calendar up and pad on right. calendar says the normal menstrual cycle typically lasts for less than 7 days and occurs every 21 to 35 days. the average woman loses about 2-3 tablespoons of blood during her period. pad says the typical cost the menstrual hygiene products is $7 to $10 per month, which adds up to between $3,360 and $4,800 over the course of a life time
Health Lab
Addressing disparities in abnormal menstrual bleeding and anemia
A large grant for Michigan Medicine will launch important research to improve the screening and treatment for a gynecologic disorder that disproportionately impacts Black and Hispanic populations
mom smiling with 3 kids
Health Lab
Adolescents with heart disease learn resilience skills, connect with peers through unique program
Youth with heart disease enrolled in unique program that teaches resilience and builds connections with their peers
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
Presenting: The Fundamentals
Today on Health Lab, we are sharing an episode of The Fundamentals, another podcast from the Michigan Medicine Podcast Network that just launched its second season earlier this month. On this episode of The Fundamentals: "Cannabis and psychedelics: stigmatized substances or powerful therapeutics?" Dr. Kevin Boehnke talks about cannabis, psychedelics, and the increasing body of evidence for their legitimization as therapeutics.